NeuroTherapia, based in Gates Mills, OH, is a pioneering biotech company that is revolutionizing the treatment of central nervous system (CNS) diseases. With a focus on neuroinflammation, they are developing oral, small molecule therapeutics that inhibit microglia cells, known to drive inflammation in the CNS, offering a novel approach that complements existing antibody therapies.
At the forefront of their innovative approach is their lead program, NTRX-07, an orally available small molecule that reduces inflammation and enhances the brain's ability to form new connections, resulting in improved learning and memory. With promising results from their Phase 1b clinical trial in Alzheimer's disease patients, NeuroTherapia is poised to make significant advancements in the treatment of CNS conditions.
Generated from the website